Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-α and macrophage inflammatory protein-2 production

European Journal of Pharmacology

Volumn 578, Issue 1, 2008, Pages 57-64

  Ishizaki, Kaoru ^a   Iwaki, Tomomichi ^a   Kinoshita, Shuji ^a   Koyama, Mamoru ^b   Fukunari, Atsushi ^b   Tanaka, Hideki ^b   Tsurufuji, Makoto ^b   Sakata, Kei ^a   Maeda, Yasuhiro ^a   Imada, Teruaki ^a   Chiba, Kenji ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Discovery Technology   (Finland)

Author keywords

Concanavalin A; Liver bile acid; Liver nonparenchymal cell; Lymph node cell; Macrophage inflammatory protein 2; Neutrophil; Tumor necrosis factor ; Ursodeoxycholic acid

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HISTOLOGY; INCIDENCE; LIVER; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MALE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; CHEMOKINE CXCL2; CHOLAGOGUES AND CHOLERETICS; CONCANAVALIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; INTERFERON TYPE II; INTERLEUKINS; LIVER; LIVER DISEASES; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID;

EID: 36549034307     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.031     Document Type: Article

References (33)

1. Combes B., Carithers Jr. R.L., Maddrey W.C., Munoz S., Garcia-Tsao G., Bonner G.F., Boyer J.L., et al. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 29 (1999) 1649-1654
2. Corpechot C., Carrat F., Bahr A., Chretien Y., Poupon R.E., and Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128 (2005) 297-303
3. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Pojer C., Zenz R., et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121 (2001) 170-183
4. Fiorrucci S., Mencarelli A., Palazzetti B., Soldato P.D., Morelli A., and Ignarro L.J. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2652-2657
5. Fukuda T., Mogami A., Hisadome M., and Komatsu H. Therapeutic administration of Y-40138, a multiple cytokine modulator, inhibits concanavalin A-induced hepatitis in mice. Eur. J. Pharmacol. 523 (2005) 137-142
6. Gantner F., Kusters S., Wendel A., Hatzelmann A., Schudt C., and Tiegs G. Protection from T-cell-mediated murine liver failure by phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 280 (1997) 53-60
7. Imose M., Nagaki M., Kimura K., Takai S., Imao M., Naiki T., et al. Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor κB. Hepatology 40 (2004) 1160-1169
8. Lazzaridis K.N., Gores G.J., and Lindor K.D. Ursodeoxycholic acid 'mechanism of action and clinical use in hepatobiliary disorders'. J. Hepatol. 35 (2001) 134-146
9. Lirussi F., Becdarello A., Bortolato L., Morselli-Labate A.M., Crovatto M., Ceselli S., Satini G., et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 19 (1999) 381-388
10. Louis H., Moine O.L., Peny M.O., Quertinmont E., Fokan D., Goldman M., and Deviere J. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 25 (1997) 1382-1389
11. Mitchell S.A., Bansi D.S., Hunt X., von Bergmann K., Fleming K.A., and Chapman R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 (2001) 900-907
12. Mitsuyoshi H., Nakashima T., Sumida Y., Yoh T., Nakajima Y., Ishikawa H., et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem. Biophys. Res. Commun. 263 (1999) 537-542
13. Miura T., Ouchida R., Yoshikawa N., Okamoto K., Makino Y., Nakamura T., et al. Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J. Biol. Chem. 276 (2001) 47371-47378
14. Nakamura K., Okada M., Yoneda M., Takamoto S., Nakade Y., Tamori K., et al. Macrophage inflammatory protein-2 induced by TNF-α plays a pivotal role in concanavalin A-induced liver injury in mice. J. Hepatol. 35 (2001) 217-224
15. Nicoletti F., Marco R.D., Zaccone P., Salvaggio A., Magro G., Klanus B., and Meroni P. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through and interferon-γ-dependent mechanism. Hepatology 32 (2000) 728-733
16. Omata, M., Yoshida, H., Toyota, J., Tomita, E., Nishiguchi, S., Hayashi, N., in press. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut.
17. Pares A., Caballeria L., Rodes J., Bruguera M., Rodrigo L., Garcia-Plaza A., Berenguer J., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-cooperative group from the spanish association for the study of the liver. J. Hepatol. 32 (2000) 561-566
18. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., and Heathcote E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113 (1997) 884-890
19. Rodrigues C.M.P., Fan G., Ma X., Kren B.T., and Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 101 (1998) 2790-2799
20. Sakakura H., Kimura N., Takeda H., Komatsu H., Ishizaki K., and Nagata S. Simultaneous determination of bile acids in rat liver tissue by high-performance liquid chromatography. J. Chromatogr. B 718 (1998) 33-40
21. Sass G., Heinlein S., Agli A., Bang R., Schumann J., and Tiegs G. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19 (2002) 115-120
22. Schierwagen C., Bylund-Fellenius A.C., and Lundberg C. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Methods 23 (1990) 179-186
23. Seglen P.O. Preparation of rat liver cells. III. Enzymatic requirements for tissue dispersion. Exp. Cell Res. 82 (1973) 391-398
24. Serviddio G., Pereda J., Pallardo F.V., Garretero J., Borras C., Cutrin J., et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 39 (2004) 711-720
25. Setchell K.D.R., Rodrigues C.M.P., Clerici C., Solinas A., Morelli A., Gartung C., and Boyer J. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112 (1997) 226-235
26. Smedsrod B., and Pertoft H. Preparation of pure hepatocytes and reticuloendothelial cells in high yield from a single rat liver by means of percoll centrifugation and selective adherence. J. Leukoc. Biol. 38 (1985) 213-230
27. Takano S., Ito Y., Yokosuka O., Ohto M., Uchiumi K., Hirota K., and Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20 (1994) 558-564
28. Tanaka H., Makino Y., Miura T., Hirano F., Okamoto K., Komura K., et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J. Immunol. 156 (1996) 1601-1608
29. Tarao K., Rino Y., Ohkawa S., Endo O., Miyakawa K., Tamai S., et al. Substained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A. Intervirology 47 (2004) 65-71
30. Tiegs G., Hentschel J., and Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90 (1992) 196-203
31. van de Meeberg P.C., Wolfhagen F.H., van Berge-Henegouwen G.P., Salemans J.M., Tangerman A., van Buuren H.R., van Hattum J., et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J. Hepatol. 25 (1996) 887-894
32. Veldt B.J., Hansen B.E., Ikeda K., Verhey E., Suzuki H., and Schalm S.W. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand. J. Gastroenterol. 41 (2006) 1087-1094
33. Yoshikawa M., Tsujii T., Matsumura K., Yamao J., Matsumura Y., Kubo R., et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16 (1992) 358-364